Center for Cancer Experimental Therapeutics

癌症实验治疗中心

• 批准号: 7936655
• 负责人: BARBARA N TIMMERMANN
• 金额: $ 110.25万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-09-01 至 2015-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7936655
• 关键词: Affinity; Area; Arts; Award; Basic Cancer Research; Biochemical; Biology; Books; Cancer Center; Cells; Centers of Research Excellence; Cities; Collaborations; Complex; Data; Drug Compounding; Funding; Goals; Grant; Housing; Human Resources; Journals; Kansas; Laboratories; Malignant Neoplasms; Manuscripts; Mission; Pharmaceutical Chemistry; Phase; Pilot Projects; Publishing; Request for Applications; Research; Research Personnel; Research Support; Screening procedure; Small Interfering RNA; Therapeutic; United States National Institutes of Health; Universities; Work; analog; base; design; drug discovery; experience; high throughput screening; instrumentation; novel; professor; programs; public health relevance; square foot; structural biology; tool

DESCRIPTION (provided by applicant): In this application we are requesting funds to continue our COBRE Center for Cancer Experimental Therapeutics (CCET) for five more years. Our center was among the first group of COBRE grants awarded in 2000. The mission of the CCET is to increase cancer-related research and NIH funding in the State of Kansas. It has been a very successful program (http://ccet.cobre.ku.edu/index.php). During the first ten years of the program our center has funded 26 full Project Awards and 27 smaller First Awards. Thirty tenure track assistant professors have received funding. Of these, 11 have been promoted with tenure and 12 are still on the tenure track. The CCET investigators have obtained 42 NIH-funded grants (17 ROIs) and 37 grants from other agencies, leading to a total of about $36,500,000 in new funding to Kansas. These investigators have published 218 journal and book manuscripts on research supported by the CCET. An essential part of our COBRE program was the establishment of two research cores, a High Throughput Screening (HTS) Core and a Medicinal Chemistry (IVIDC) Core. The COBRE Cores are located in the Structural Biology Center (SBC) located on the University of Kansas West Campus. The modern 4,500 sq.ft. High Throughput Screening Core research/office complex is fully equipped with state-of-the-art instrumentation and the personnel have extensive experience in executing cell-based, biochemical, labelfree, siRNA as well as high content screening campaigns. The primary goal of the HTS Core has been to make modern drug discovery tools available to biomedical researchers in the Greater Kansas City area, Kansas and beyond. The equally modern Medicinal Chemistry Core is housed in a laboratory of approximately 2000 square feet. The MDC Core works in conjunction with the HTS Core and in collaboration with COBRE investigators and other researchers. The tasks of the MDC Core are (1) to perform synthesis of known compounds necessary for biochemical studies, (2) to design and synthesize novel drug compounds as probes for ongoing studies, (3) to work with the HTS Core and its biology collaborators in carrying out optimization of hits obtained in screening campaigns, and (4) to synthesize fluorescent or affinity tagged analogs of existing probes when necessary for cell localization or target identification studies. In this Phase III application we are requesting funds to continue these successful research cores and to make them self-sustaining by the end of the five-year funding. In addition, we seek funding to support a Pilot Project program to help basic cancer research investigators obtain preliminary data to strengthen their applications to agencies for major funding. We plan to fund four projects per year. Finally, we request support for an Administrative Core to oversee the entire program, including the Pilot Project program and the two research cores. PUBLIC HEALTH RELEVANCE (provided by applicant): The mission of the CCET is to increase cancer-related research and NIH funding in the State of Kansas.

描述（由申请人提供）：在此申请中，我们请求资金来继续我们的 COBRE 癌症实验治疗中心 (CCET) 五年。我们的中心是 2000 年第一批获得 COBRE 资助的中心之一。CCET 的使命是增加堪萨斯州与癌症相关的研究和 NIH 的资助。这是一个非常成功的计划（http://ccet.cobre.ku.edu/index.php）。在该计划的前十年中，我们中心资助了 26 个完整项目奖和 27 个较小的一等奖。三十名终身教授助理教授已获得资助。其中，11 人已晋升为终身教职，12 人仍在终身教职。 CCET 研究人员已获得 42 项 NIH 资助的资助（17 个 ROI）和 37 项其他机构的资助，为堪萨斯州带来总计约 36,500,000 美元的新资金。这些研究人员已发表了 218 篇有关 CCET 支持的研究的期刊和书籍手稿。我们 COBRE 计划的一个重要部分是建立两个研究核心，即高通量筛选 (HTS) 核心和药物化学 (IVIDC) 核心。 COBRE 核心位于堪萨斯大学西校区的结构生物学中心 (SBC)。现代化的 4,500 平方英尺。高通量筛选核心研究/办公综合体配备了最先进的仪器，人员在执行基于细胞、生化、无标记、siRNA 以及高内涵筛选活动方面拥有丰富的经验。 HTS Core 的主要目标是为大堪萨斯城地区、堪萨斯州及其他地区的生物医学研究人员提供现代药物发现工具。同样现代化的药物化学核心位于约 2000 平方英尺的实验室中。 MDC Core 与 HTS Core 协同工作，并与 COBRE 研究人员和其他研究人员合作。 MDC Core 的任务是 (1) 合成生化研究所需的已知化合物，(2) 设计和合成新型药物化合物作为正在进行的研究的探针，(3) 与 HTS Core 及其生物学合作者合作对筛选活动中获得的命中进行优化，以及 (4) 在细胞定位或目标识别研究需要时合成现有探针的荧光或亲和标记类似物。在此第三阶段申请中，我们请求资金来继续这些成功的研究核心，并使其在五年资助结束时能够自我维持。此外，我们还寻求资金来支持试点项目计划，以帮助基础癌症研究人员获得初步数据，以加强他们向机构申请主要资金的能力。我们计划每年资助四个项目。最后，我们请求支持行政核心来监督整个计划，包括试点项目计划和两个研究核心。 公共卫生相关性（由申请人提供）：CCET 的使命是增加堪萨斯州的癌症相关研究和 NIH 资助。